Drugs / AGEN1223
last change Sep 2021 re-read 2 minutes ago

AGEN1223

Developed for
neoplasm
Investigated by
Agenus Inc.

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04156100 Dec 2019 → Apr 2021 neoplasm Agenus Inc. Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AGEN1223 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04156100